Dr. Henske is renowned for her discovery that mutations in the TSC2 gene cause the sporadic form of lymphangioleiomyomatosis (LAM), a rare lung disease of women. The symptoms of LAM, which can include chest pain, shortness of breath, lung collapse, and lung failure, usually begin in early adulthood. Her discovery provided the basis for key clinical trials demonstrating the effectiveness of mTOR (mammalian target of rapamycin) inhibition with sirolimus/rapamycin for the treatment of LAM. Dr. Henske is a Physician at Brigham and Women’s Hospital, where she is Director of the Center for LAM Research and Clinical Care. She is also Professor of Medicine at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute. She has received grant funding from NHLBI to study the molecular and genetic underpinnings of LAM as well as explore novel therapeutic strategies for LAM.